Dividend Policy & Yield
Cardinal Health has a long history of paying quarterly dividends, albeit with slow growth in recent years. In fiscal 2025 (year ended June 30, 2025), Cardinal paid $2.02 per share in dividends, a roughly 1% increase from $2.00 in 2024 (www.sec.gov). The board approved a slight raise to an annualized $2.04 per share starting July 2025 (www.sec.gov), continuing the pattern of penny-sized increases (the dividend was $1.98 in 2023) (www.sec.gov). Because Cardinal’s stock price has surged – recently around $200+ per share after a ~92% gain over the past year (artificall.com) – the dividend yield has compressed to roughly 1% (www.sec.gov) (artificall.com). This yield is low by the company’s historical standards (when the stock was cheaper, yield ranged 3–4%), reflecting the market’s rerating of Cardinal’s earnings. Importantly, the dividend payout appears well-covered by profits. Fiscal 2025 net income was about $1.56 billion (www.sec.gov) (www.sec.gov), meaning only ~32% of earnings were paid out as dividends (~$494 million cash dividends) (www.sec.gov). Even on a cash-flow basis, Cardinal’s operations comfortably fund the dividend, as evidenced by consistent free cash generation and a trend of additional cash uses like share buybacks ($765 million in FY2025) (www.sec.gov) (www.sec.gov). Shareholders thus enjoy a reliable (if modest) income stream, and Cardinal’s dividend policy shows commitment to steady payouts – though meaningful growth in the dividend will likely hinge on stronger earnings growth or strategic shifts in capital allocation.
Leverage, Debt Maturities & Coverage
After a series of acquisitions in fiscal 2025, Cardinal’s debt load has increased, but remains moderate relative to its scale. Total long-term debt stood at $8.5 billion as of June 30, 2025 (www.sec.gov). The company raised $2.9 billion in November 2024 through multi-tranche bond issuance to help fund two major deals – the buyouts of Advanced Diabetes Supply (ADS) and a majority stake in GI Alliance (GIA) – and an oncology network acquisition (www.sec.gov) (www.sec.gov). These new notes include $500 million of 4.7% bonds due 2026, $750 million of 5.0% bonds due 2029, $1.0 billion of 5.35% bonds due 2034, and $650 million of 5.75% bonds due 2054 (www.sec.gov) (www.sec.gov), indicating Cardinal locked in longer-term financing at fixed rates amid a higher interest-rate environment.
Despite the debt uptick, liquidity is solid. Cardinal held $3.9 billion in cash at fiscal year-end (www.sec.gov), making net debt roughly ~$4.6 billion (net of cash). It also maintains substantial short-term borrowing capacity via a $3.0 billion commercial paper program backstopped by credit facilities (www.sec.gov) (www.sec.gov). Near-term debt maturities are manageable: about $0.5 billion is due within one year, and roughly $2.6 billion falls due in the following two years (www.sec.gov). The maturity profile then stretches out, with ~$1.4 billion in years 3–5 and ~$3.8 billion beyond year 5 (2031+), including the long-dated 2054 bonds (www.sec.gov) (www.sec.gov). This staggered schedule limits refinancing risk.
Coverage ratios remain comfortable. In FY2025, Cardinal’s operating earnings were $2.3 billion (GAAP) and $2.8 billion on an adjusted basis (www.sec.gov), while interest expense was $215 million (www.sec.gov). Thus, even after the new debt, EBIT covers interest about 10× (over 12× on a non-GAAP EBIT basis) – a strong cushion. The interest coverage and an Altman Z-score in the safe zone (~4.9) signal low default risk (artificall.com). Leverage as measured by debt-to-EBITDA is modest (roughly 2.7× using ~$3.1 B EBITDA (artificall.com)), and management is maintaining a mix of fixed and floating-rate debt to balance interest rate exposure (www.sec.gov). Overall, Cardinal’s balance sheet can support its strategy: the company used debt opportunistically for growth initiatives, yet retains financial flexibility and investment-grade credit characteristics.
Valuation and Performance Metrics
Cardinal Health’s valuation has expanded significantly following its operational turnaround and investor optimism. At around $210 per share in early 2026, the stock trades at roughly 24× Cardinal’s FY2025 adjusted earnings (non-GAAP EPS of $8.24) (www.sec.gov) (www.sec.gov). On a GAAP basis, the P/E is closer to 31× (net income $6.45 per share) (www.sec.gov) – a notable rerating from just a couple of years ago when the stock languished under $70 (P/E in the low teens) (www.cnbc.com). This richer multiple reflects Cardinal’s improved profitability and growth prospects. In FY2025, revenue was $222.6 billion (www.sec.gov) (a slight 2% dip due to losing a large OptumRx contract, which had inflated prior-year sales (www.sec.gov)), but gross margin and operating income jumped. GAAP operating profit doubled year-on-year to $2.3 billion (www.sec.gov), and non-GAAP op profit rose 15% to $2.8 B, thanks to stronger contributions from specialty pharmaceuticals and the absence of last year’s impairment charges (www.sec.gov) (www.sec.gov). Net profit margin, while still slim (≈0.7% of sales), improved markedly (artificall.com). These gains underscore Cardinal’s post-activist efficiency efforts and a more favorable sales mix (higher-margin specialty drugs and services).
Compared to peers, Cardinal’s valuation is now in line or slightly elevated. Cencora (COR) – formerly AmerisourceBergen – and McKesson (MCK) historically traded at lower earnings multiples, but have also seen stock appreciation. For instance, Cardinal’s market cap (~$48 B) and net income (~$1.56 B) are similar to Cencora’s ($65 B and $1.55 B, respectively), yet Cardinal’s stock outperformed with +92% in 2025 vs. +45% for Cencora (artificall.com). EV/EBITDA for Cardinal is in the mid-teens, reflecting the low-margin, high-volume nature of distribution businesses, but also investor confidence in recent strategic moves. That said, analysts see limited upside from current levels: the consensus target price is about $215, roughly where the stock trades (artificall.com). In short, Cardinal Health is no longer a “value stock” – it’s priced for its safer earnings profile and improved growth trajectory. Continued execution will be needed to justify these higher multiples.
Risks and Red Flags
Despite its positive momentum, Cardinal Health faces several risks and potential red flags that investors should monitor:
- Opioid Litigation Liabilities: As one of the distributors implicated in the U.S. opioid crisis, Cardinal is paying out a major settlement over nearly two decades. The company had $4.9 billion accrued for opioid settlement obligations at June 2025 (www.sec.gov), with roughly $4.8 billion in cash outflows remaining through 2038 (www.sec.gov). Annual payments (around $366 M in 2025) will weigh on cash flows for years (www.sec.gov). While reserved and scheduled, this is essentially a debt-like liability. Any unexpected legal developments – e.g. new lawsuits or higher-than-anticipated claims – could create additional financial strain (www.sec.gov) (www.sec.gov). There is also reputational risk; the opioid saga damaged trust in distributors, and continued scrutiny or related regulations could emerge (www.sec.gov) (www.sec.gov).
- Thin Margins & Pricing Pressures: Cardinal operates on razor-thin margins (gross margin ~3.7% of sales (www.sec.gov) (www.sec.gov), net margin <1% (artificall.com)). Small changes in cost or pricing can thus have outsized effects on profit. Generic drug price deflation is a perennial concern – if generic pricing declines or slows (reducing the benefit of Cardinal’s purchasing scale), distribution profit can stagnate or fall. Conversely, if drug prices rise, Cardinal faces LIFO inventory accounting charges (as seen in past periods), which can hurt GAAP earnings (www.sec.gov). The company excludes LIFO swings in its non-GAAP results (www.sec.gov), but real cash flow could be impacted by inventory cost timing. Cardinal also must manage inflation in operating costs (labor, fuel for logistics, etc.) while contract structures often cap pass-through to customers, potentially squeezing margins.
- Customer Concentration: A few large customers dominate Cardinal’s revenue. In fact, the top five customers account for ~43% of revenue (www.sec.gov), with CVS Health alone around 9% (www.sec.gov). The loss of any big contract or group purchasing organization (GPO) relationship can materially dent sales and profits. This happened in FY2025 when the OptumRx bulk contracts ended, causing a revenue drop and working-capital unwinding (www.sec.gov) (www.sec.gov). Cardinal notes that two major GPOs (Vizient and Premier) drive over a quarter of its sales (www.sec.gov) – if these were to switch partners or negotiate tougher terms, Cardinal’s volumes and leverage could suffer. Credit risk is also relevant: several retail pharmacy chains have struggled (e.g. Rite Aid’s bankruptcy). A large customer bankruptcy or non-payment could hit Cardinal with receivables losses or mini-shocks to distribution volumes.
- Integration of Acquisitions: Cardinal’s recent pivot toward higher-margin platforms brings integration risk. The company spent $5.3 billion in FY2025 on acquisitions (www.sec.gov) – including GI Alliance (a gastroenterology practice MSO), Urology America (urology MSO), ION (oncology clinics network), and ADS (home diabetes supplies) (www.sec.gov) (www.sec.gov). These moves aim to diversify Cardinal’s business beyond traditional distribution into medical services and direct-to-patient supply channels. However, managing physician practice groups and home-care supply is a new arena for Cardinal. Execution will be key: there are cultural and operational challenges in integrating these into Cardinal’s corporate structure. There’s a risk of overpayment or goodwill write-downs if earnings from these acquisitions fall short. (Notably, Cardinal took a $675 M goodwill impairment on its medical segment in 2024 (www.sec.gov), underscoring how past diversification moves – e.g. prior medical product deals – hadn’t met expectations.) Any stumbles in these new ventures could erode the improved investor confidence.
- Regulatory and Structural Uncertainties: Cardinal operates in a heavily regulated space. Changes in healthcare policy – for instance, new drug pricing legislation, altered reimbursement models, or stricter distribution controls – could impact profitability. Additionally, major strategic changes by competitors or suppliers pose risks. For example, if large pharmaceutical manufacturers alter distribution arrangements (say, moving to direct distribution or Amazon-like channels), Cardinal’s intermediary role could be pressured. So far, the “Big Three” have maintained their critical place in the supply chain, but technological disruption or disintermediation is a longer-term threat. Cardinal must also keep investing in cybersecurity and systems; a serious IT failure or data breach in the distribution network would be highly disruptive (and potentially costly legally). Lastly, activist expectations remain in the background – Elliott Management’s involvement in 2022 brought governance changes and a business review (www.cnbc.com) (www.prnewswire.com). If Cardinal’s performance slips, pressure could mount for more drastic measures (such as splitting the pharma and medical segments).
Open Questions & Outlook
As Cardinal Health moves forward, several open questions will shape its investment thesis. First, will the company continue its foray into higher-margin healthcare services? Early signs suggest the acquired MSO (Management Services Organization) platforms in gastroenterology, urology, and oncology are boosting segment profits (www.sec.gov). But investors will want to see sustained earnings contributions and synergies from these deals – essentially, proof that Cardinal can successfully diversify its revenue base. Another question is capital allocation: with the stock price elevated, will Cardinal pivot more to bolt-on growth investments or return more cash to shareholders? The dividend increases have been minimal, so perhaps accelerated buybacks or a dividend boost could be on the table if cash flows remain strong (especially once opioid payments begin to taper in the 2030s).
It’s also worth watching whether Cardinal’s valuation premium holds. At ~24× forward earnings, the stock anticipates continued profit growth and stability. Any misstep – an earnings miss, integration hiccup, or macro headwind – could lead to a pullback. Notably, Wall Street’s price targets (around $215 (artificall.com)) imply only modest upside, suggesting the easy gains may be behind us after the stock’s huge run. In the near term, the Crinetics CAH trial itself is more quirk than catalyst for Cardinal – but it highlights the constant innovation in healthcare. If Crinetics’ new therapy for congenital adrenal hyperplasia succeeds, Cardinal’s specialty distribution arm would likely handle its delivery to patients, reinforcing how any medical breakthrough eventually flows through distributors. In that sense, Cardinal Health remains a linchpin of the healthcare system – its fortunes tied to overall drug demand and health trends. The company’s challenge is to manage its legacy distribution business efficiently while capitalizing on new opportunities in healthcare services. If it strikes that balance, Cardinal can justify its newfound market esteem. Big news or small, Cardinal Health’s execution will ultimately determine whether the recent rally and premium valuation are sustainable.
Sources: Cardinal Health FY2025 10-K (www.sec.gov) (www.sec.gov) (www.sec.gov); CNBC (www.cnbc.com); Cardinal Health Investor Releases (www.prnewswire.com); artificall.com (Cencora vs. Cardinal) (artificall.com) (artificall.com); Stock Titan/Crinetics (www.stocktitan.net).
